Literature DB >> 22781383

Overall survival analysis of adjuvant radiation versus observation in stage I testicular seminoma: a surveillance, epidemiology, and end results (SEER) analysis.

Guy Jones1, Benjamin Arthurs, Hakan Kaya, Kenneth Macdonald, Rui Qin, Robert K Fairbanks, Wayne T Lamoreaux, Irfan Jawed, Jonathan D Tward, Danko Martincic, Anand T Shivnani, Christopher M Lee.   

Abstract

OBJECTIVE: The standard adjuvant treatment for men with stage I testicular seminoma remains controversial within the literature. We analyzed survival rates in men with stage I seminoma who underwent adjuvant radiation therapy (RT) or observation (OB) after orchiectomy.
METHODS: Data were obtained from the Surveillance, Epidemiology, and End Results program of the National Cancer Institute from 1973 to 2003. The primary end points were overall survival (OS) and cause-specific survival (CSS). Multivariate Cox regression models were used to study the significance of clinical variables: age at diagnosis, laterality of primary disease, race, and radiation group.
RESULTS: Of 6764 patients eligible for analysis, 5265 were treated with RT and 1499 with OB. After a median follow-up of 7.6 years, the 5-, 10-, and 20-year OS rates for the RT versus OB were 97.9 versus 95.0, 94.8 versus 92.2, and 83.5 versus 84.1 (P=0.0047), respectively. The CSS rates for the same time periods were 99.6 versus 98.7, 99.4 versus 98.7, and 99.2 versus 98.7 (P=0.0015), respectively. Adjuvant RT was associated with improved CSS on multivariate analysis with hazard ratio of 0.37 (confidence interval, 0.20-0.70; P=0.0023).
CONCLUSIONS: Within this large US population analysis, adjuvant RT was associated with improved OS and CSS compared with OB for men with stage I testicular seminoma. Further studies are needed to determine whether modern RT techniques and field-size reductions may lead to greater improvements in the therapeutic ratio, in light of the trend toward chemotherapy as primary treatment.

Entities:  

Mesh:

Year:  2013        PMID: 22781383     DOI: 10.1097/COC.0b013e318254950a

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  5 in total

Review 1.  Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases.

Authors:  K Rai; R Pilarski; C M Cebulla; M H Abdel-Rahman
Journal:  Clin Genet       Date:  2015-07-14       Impact factor: 4.438

2.  Treatment preferences in stage IA and IB testicular seminoma: multicenter study of Anatolian Society of Medical Oncology.

Authors:  Ahmet Bilici; Turkan Ozturk; Esma Turkmen; Hatice Odabas; Sener Cihan; Fatih Selcukbiricik; Bulent Erdogan; Zurat Urakci; Nurten Kandemir; Ibrahim Vedat Bayoglu; Umut Demirci; Ayse Ocak Duran; Mehmet Ali Nahit Sendur; Dilek Yavuzer; Hakan Harputluoglu; Halil Kavgaci; Mahmut Gumus
Journal:  World J Urol       Date:  2015-01-21       Impact factor: 4.226

3.  Testicular germ cell tumours' clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival-a systematic review.

Authors:  Christian G Ruf; Stefanie Schmidt; Sabine Kliesch; Christoph Oing; David Pfister; Jonas Busch; Julia Heinzelbecker; Christian Winter; Friedemann Zengerling; Peter Albers; Karin Oechsle; Susanne Krege; Julia Lackner; Klaus-Peter Dieckmann
Journal:  World J Urol       Date:  2022-09-15       Impact factor: 3.661

Review 4.  Management of stage I testicular germ cell tumours.

Authors:  Michal Chovanec; Nasser Hanna; K Clint Cary; Lawrence Einhorn; Costantine Albany
Journal:  Nat Rev Urol       Date:  2016-09-13       Impact factor: 14.432

Review 5.  Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach.

Authors:  Hester Lieng; Padraig Warde; Philippe Bedard; Robert J Hamilton; Aaron R Hansen; Michael A S Jewett; Martin O'malley; Joan Sweet; Peter Chung
Journal:  Can Urol Assoc J       Date:  2017-12-01       Impact factor: 1.862

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.